Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5752W HIGH $2.80
Volume
18.57 K
Value Traded
13.57 K
Short % Float
0.56%
Days to Cover
1.2
-17.43%Week
-20.61%1 Month
-22.39%3 Month
-28.7%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.92 M
EPS (TTM)
-0.33
P/E Ratio
-
Ent. Value
465.37 K
Total Shares
5.52 M
Float Shares
4.85 M
Insiders
26.76%
Institutions
1.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
BGMS Catalyst Timeline
Dated clinical, regulatory and corporate events for Bio Green Med Solution, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bio Green Med Solution, Inc.
506Total events
3Upcoming
82Tier-1 (high impact)
2010 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Quarterly UpdateCorporate
BGMS reports third quarter 2026 financial results and business update
◆AcquisitionCorporate
Bio Green Med Solution enters into Business Combination Agreement to acquire Future NRG Sdn. Bhd.
▼Equity OfferingCorporate
Entered into Securities Purchase Agreement for $794,403 gross proceeds
▲Partnership / LicenseplogosertibDiscontinuedCorporate
Sale of Plogosertib assets to Tethra Biosciences
advanced cancers and hematological malignanciessource ↗
▼Program DiscontinuationplogosertibDiscontinuedCorporate
Plogosertib program paused and subsequently sold
◆Timing GuidancePresentation
Expected closing date of Transaction on or before August 31, 2025
●Quarterly UpdateCorporate
Company comments on recent stock price volatility, no material adverse changes
◆AcquisitionCorporate
Amendment to Exchange Agreement with FITTERS Diversified Berhad announced
▼Equity OfferingCorporate
Private placement of convertible Series F Preferred Stock and warrants for $3.0 million gross proceeds
▼Going ConcernCorporate
Company analyzing strategic alternatives to continue as going concern
◆AcquisitionCorporate
Cyclacel enters into share exchange agreement to acquire Fitters Sdn. Bhd.
▼Equity OfferingCorporate
Exchange agreement with FITTERS Diversified Berhad for 19.99% common stock
●Quarterly UpdateCorporate
Cyclacel reports Q4 2024 financial results and provides business update
●Management ChangeCorporate
Appointment of Inigo Angel Laurduraj and Dr. Satis Waran Nair Krishnan as independent directors
▼Program DiscontinuationfadraciclibDiscontinuedCorporate
Cyclacel Limited liquidation leads to deconsolidation of fadraciclib program
◆Management ChangeCorporate
Notice of resignation of Avraham Ben-Tzvi and David Natan as independent directors effective upon filing of 10-K or March 31, 2025
▼Equity OfferingCorporate
Closed $1 million private placement of convertible Series E Preferred Stock
◆Pipeline PrioritizationplogosertibDiscontinuedCorporate
Company focuses on plogosertib clinical program only
▲Partnership / LicenseplogosertibDiscontinuedCorporate
Cyclacel acquires plogosertib from Cyclacel Limited
advanced cancers and hematological malignanciessource ↗
◆AcquisitionCorporate
Closing of change of control transaction: Datuk Dr. Doris Wong Sing Ee acquires 70% of Cyclacel shares
◆Management ChangeCorporate
Resignation of directors Samuel L. Barker, Paul McBarron, and Spiro Rombotis
▼Going ConcernCorporate
Nasdaq deadline to demonstrate compliance with minimum stockholders' equity requirement is February 6, 2025
▼Program DiscontinuationfadraciclibDiscontinuedCorporate
Fadraciclib program discontinued due to Cyclacel Limited liquidation
▼Program DiscontinuationCorporate
UK subsidiary Cyclacel Limited liquidated; transcriptional regulation program ceased
▼Program DiscontinuationfadraciclibDiscontinuedCorporate
Liquidation of UK subsidiary Cyclacel Limited; cessation of fadraciclib program
◆Management ChangeCorporate
David Lazar appointed as interim CEO; Spiro Rombotis stepped down as CEO
▼Restructuring LayoffsCorporate
Board directed management to reduce operating costs while exploring strategic alternatives
◆Management ChangeCorporate
Nasdaq extension granted until December 24, 2024 to regain compliance with minimum stockholders' equity requirement
Past FDA Catalysts and PDUFA Decisions
How BGMS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BGMS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Yap Kim Choy10% Owner | Sell | -28,540 | $1.70 | 11/05/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in BGMS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BGMS for Q2 2026. | ||||
Ownership Trends
BGMS Short Interest
Shares sold short, counted twice a month.
0.56%
Short % of Float
of tradable shares sold short
27.1K
Shares Sold Short
-10.2% vs prior count
1.2 Low
Days to Cover
trading days of normal volume to buy every short share back
23.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BGMS ranks across every disease it competes in
Competitive Position is a premium feature
See how BGMS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBGMS News
BGMS▲ +6%today
BIO GREEN MED SOLUTION REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Bio Green Med Solution reported its third quarter financial results, highlighting a significant increase in product revenue to $454,000 and a narrowed net loss of $0.4 million. The company also declared a quarterly cash dividend of $0.15 per share. General and administrative expenses were reduced by 37% year over year, indicating improved financial management.
Read more →BGMSBIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Bio Green Med Solution, Inc. reported its second quarter financial results, highlighting a significant reduction in net loss and a focus on fire safety protection. The company entered a Business Combination Agreement with Future NRG and secured funding through a Securities Purchase Agreement. Despite positive developments, existing shareholders will see a diluted ownership stake post-acquisition.
Read more →BGMSBio Green Med Solution, INC. Announces Business Combination Agreement to acquire Future NRG Sdn. Bhd.
Bio Green Med Solution, Inc. (BGMS) has entered into a Business Combination Agreement to acquire Future NRG Sdn. Bhd. This deal aims to establish a scalable platform integrating essential safety and environmental services focusing on compliance-driven industries. The combination is anticipated to enhance the service offerings to healthcare waste generators and improve revenue through bundled compliance solutions. Future NRG specializes in sustainable waste management, providing advanced waste-to-energy solutions. The transaction is set to close in the fourth quarter of 2026, pending shareholder approvals.
Read more →BGMS▲ +5%on this news
BIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Bio Green Med Solution, Inc. (BGMS) reported its first quarter financial results for 2026, highlighting a strategic shift towards fire safety operations. The company generated $0.8 million in product revenue and reduced general and administrative expenses significantly. Despite a modest net loss of $0.2 million, BGMS maintains a strong cash position to support future growth.
Read more →BGMSBIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Bio Green Med Solution, Inc. (BGMS) reported its fourth quarter and full year 2025 financial results, highlighting a productive year marked by key acquisitions and strategic sales. The company successfully sold its Plogosertib drug and acquired Fitters Sdn. Bhd., shifting its focus to fire safety protection. Despite a net loss of $3.0 million, BGMS declared a quarterly dividend, reflecting ongoing financial management efforts.
Read more →BGMS▼ -6.9%on this news
Bio GREEN MED SOLUTION Reports THIRD quarter financial results and provides business update
Bio Green Med Solution, Inc. (BGMS) reported its third-quarter financial results, highlighting a strategic shift from biopharmaceutical activities to fire safety solutions. The company recently completed its acquisition of Fitters Sdn. Bhd. and is focusing on expanding its capabilities in fire safety. Despite an increase in cash reserves, the company reported a loss of $1.0 million for the quarter. Additionally, the liquidation of its UK subsidiary has resulted in the loss of R&D tax credits.
Read more →BGMSBio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.
Bio Green Med Solution, Inc. has successfully closed the acquisition of Fitters Sdn. Bhd., a Malaysian-based company specializing in fire safety equipment. This strategic acquisition allows Bio Green Med to diversify its operations beyond pharmaceuticals into the fire protection sector. The deal was validated by stockholder approval and has resulted in Fitters being integrated as a wholly-owned subsidiary. CEO Datuk Dr. Doris Wong noted the potential for exploring new opportunities and creating long-term value for shareholders through this integration.
Read more →BGMSPharmaceuticals Reports SECOND quarter financial results and provides business update
Cyclacel Pharmaceuticals, Inc. reported its second quarter financial results for 2025, revealing a cash increase to $4.3 million. Operating expenses decreased significantly from the previous year, leading to an improved net loss of $1.3 million compared to $3.3 million in Q2 2024. However, the liquidation of its UK subsidiary has resulted in the loss of eligibility for research and development tax credits, posing potential challenges for future financing and operational stability.
Read more →BGMSLumpur, Malaysia, July 16, 2025 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today commented on recent stock price volatility.
Cyclacel Pharmaceuticals, Inc. addressed recent stock price volatility, indicating that it is unaware of any material changes in its operating conditions. The company reaffirmed that no adverse developments have been disclosed beyond their public announcements, including an amendment to their Exchange Agreement with FITTERS. Cyclacel is actively developing innovative cancer therapies, though they note potential risks associated with stockholder approvals and transaction closure conditions.
Read more →BGMSPharmaceuticals ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
Cyclacel Pharmaceuticals has announced an amendment to its Exchange Agreement with FITTERS Diversified Berhad, allowing for Fitters Sdn. Bhd. to become a wholly-owned subsidiary. In exchange for shares, Cyclacel will issue common stock equal to 19.99% of its outstanding shares and provide $1 million in cash. The agreement was unanimously approved by the boards of both companies, but is contingent on stockholder approval and regulatory clearances. The expected closing date has been extended to September 30, 2025.
Read more →BGMSPharmaceuticals ANNOUNCES STOCK SPLIT
Cyclacel Pharmaceuticals, Inc. has announced a 1-for-15 reverse stock split effective July 7, 2025. This decision, approved by both the board of directors and shareholders, aims to enhance the stock's marketability without altering shareholder percentage interest. Post-split, the number of issued shares will decrease from approximately 23.76 million to about 1.58 million. Cyclacel is developing innovative cancer treatments, including plogosertib, while facing inherent risks in clinical developments and market dynamics.
Read more →BGMSPHARMACEUTICALS ANNOUNCES $3 MILLION PRIVATE PLACEMENT OFFERING OF CONVERTIBLE PREFERRED STOCK
Cyclacel Pharmaceuticals, Inc. has announced a private placement offering of convertible preferred stock, yielding gross proceeds of $3 million. The funding will be utilized for working capital and general corporate purposes, potentially extending the company's cash runway into the third quarter of 2025. Additionally, investors will receive purchase warrants for shares of common stock at specified exercise prices. This financing aligns with Cyclacel's ongoing development of innovative cancer medicines.
Read more →BGMSPharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price RequiremenT
Cyclacel Pharmaceuticals, Inc. has announced that it has regained compliance with the Nasdaq Minimum Bid Price Requirement as of June 3, 2025. The company received a Compliance Notice indicating that its stock price has met the required $1.00 minimum for a consecutive 15-day period from May 12 to June 2, 2025. This follows a previous notification in December 2024 regarding non-compliance. The achievement reflects positively on Cyclacel's standing on the Nasdaq Stock Market.
Read more →BGMSPharmaceuticals Reports FIRST quarter financial results and provides business update
Cyclacel Pharmaceuticals has announced its first-quarter financial results, highlighting a focus on developing plogosertib following the liquidation of its subsidiary, Cyclacel Limited. The company reported a gain of approximately $5.0 million from the deconsolidation of Cyclacel Limited, although it also anticipates a significant decrease in research and development expenses. The ongoing analysis of strategic alternatives reflects a challenging funding environment. As of March 31, 2025, the company's cash balance stood at $3.5 million, which they estimate will support planned programs into the second quarter.
Read more →BGMSPharmaceuticals, INC. Announces EXECUTION OF Share Exchange Agreement to Make Fitters Sdn. Bhd. its Wholly-owned Subsidiary to Accelerate Growth and STOCKholder Value
Cyclacel Pharmaceuticals, Inc. announced the execution of a Share Exchange Agreement to acquire Fitters Sdn. Bhd., a Malaysian subsidiary of FITTERS Diversified Berhad. This strategic move is designed to accelerate growth and enhance shareholder value. Upon finalizing the transaction, Cyclacel will issue shares equivalent to 19.99% of its common stock to FITTERS, and its stockholders are expected to maintain an 80.01% ownership stake. The completion of the transaction is subject to approval from both companies’ stockholders.
Read more →BGMSPharmaceuticals Reports FOURTH quarter financial results and provides business update
Cyclacel Pharmaceuticals, Inc. reported its fourth quarter financial results and outlined a strategic focus on the development of plogosertib, a treatment for advanced cancers. The company initiated the liquidation of Cyclacel Limited, resulting in a significant reduction of operating costs and research and development expenses. The deconsolidation is expected to boost stockholders' equity, despite reporting a net loss of $11.2 million for the year. The appointment of new board members aims to strengthen governance as the company navigates through its challenges.
Read more →BGMSCYCLACEL PHARMACEUTICALS ANNOUNCES $1 MILLION PRIVATE PLACEMENT OFFERING OF CONVERTIBLE PREFERRED STOCK
Cyclacel Pharmaceuticals announced a $1 million private placement of convertible preferred stock to accredited investors. This financing aims to support working capital requirements and is anticipated to extend the company's cash runway into the third quarter of 2025. Each convertible share is designated to convert into common stock pending stockholder approval, and the offering was executed independently by the company without an underwriter.
Read more →BGMSCYCLACEL PHARMACEUTICALS ANNOUNCES CLOSING OF A CHANGE OF CONTROL TRANSACTION AND APPOINTMENT OF NEW EXECUTIVE LEADERSHIP
Cyclacel Pharmaceuticals announced a significant change in control and leadership following the acquisition of 70% of its shares by Datuk Dr. Doris Wong Sing Ee. This transaction involved a total consideration of $6.3 million and resulted in her election as CEO, succeeding former interim CEO David Lazar. Alongside her, Kiu Cu Seng was appointed as Executive Director and CFO. Several board members resigned on the same date, paving the way for new governance aimed at driving the company’s growth and value creation.
Read more →BGMSCyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
Cyclacel Pharmaceuticals announced a securities purchase agreement with investor David Lazar, who will invest $3.1 million in preferred stock, becoming the interim CEO. The investment aims to aid in settling outstanding liabilities and other corporate purposes. However, the company faces risks, including the need for stockholder approvals for the transaction and potential delisting from Nasdaq if compliance is not regained by February 2025. The Board of Directors will also see changes, impacting the company's strategic direction.
Read more →About Bio Green Med Solution, Inc.
Headquarters200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ, 07922
BIOPHARMAWATCH ELITE
Trade the next BGMS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime